Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19

Background: SARS-CoV-2-specific antibodies may protect from reinfection and disease, providing the rationale for administration of plasma containing SARS-CoV-2 neutralizing antibodies (nAb) as a treatment for COVID-19. The clinical factors and laboratory assays to streamline plasma donor selection,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:medRxiv
Autors principals: Boonyaratanakornkit, Jim, Morishima, Chihiro, Selke, Stacy, Zamora, Danniel, McGuffin, Sarah, Shapiro, Adrienne E, Campbell, Victoria L, McClurkan, Christopher L, Jing, Lichen, Gross, Robin, Liang, Janie, Postnikova, Elena, Mazur, Steven, Chaudhary, Anu, Das, Marie K, Fink, Susan L, Bryan, Andrew, Greninger, Alex L, Jerome, Keith R, Holbrook, Michael R, Gernsheimer, Terry B, Wener, Mark H, Wald, Anna, Koelle, David M
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7553186/
https://ncbi.nlm.nih.gov/pubmed/33052361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.10.06.20207472
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars